| Lorentzen Josefine |
structural insight on the function of properdin in the alternative pathway
|
| Pedersen Dennis |
structural insight on the function of properdin in the alternative pathway
|
| Adegbuyi George |
Complement Factor B activation test specificity in the rapid test format: generation and characterization of new Ba neo-epitope specific monoclonal antibodies
|
| Adler Anna |
An alternative binding and activation mechanism of native C3 induced by contact with biosurfaces without involvement of the thioester
|
| Afzali Ben |
C5a-licensed phagocytes drive sterilizing immunity during systemic fungal infection
|
| Aiuti Alessandro |
The mannose-binding lectin (MBL) in MIS-C: relationship between MBL genotype, levels, and functional activity against SARS-CoV-2
|
| Amal Haitham |
Aberrant protein S-nitrosylation of C3 activates phagocytosis of neuronal synapses by microglia in Alzheimer's disease
|
| Andersen Gregers |
structural insight on the function of properdin in the alternative pathway
|
| Anstadt Robert |
Age-related Macular Degeneration: a Tale of Two RPE-centric Diseases, of Which Only One is Complement-driven
|
| Arguelles Gabriel |
Distinct cell-bound complement activation products associate with disease activity and immune transcriptional programs in systemic lupus erythematosus
|
| Asselta Rosanna |
The mannose-binding lectin (MBL) in MIS-C: relationship between MBL genotype, levels, and functional activity against SARS-CoV-2
|
| Atkinson John |
Distinct cell-bound complement activation products associate with disease activity and immune transcriptional programs in systemic lupus erythematosus
Natural antibody targeted complement inhibitor ameliorates the development of chronic heart and lung transplant rejection
|
| Ayoub Ikram |
Cerebrospinal fluid proteomics in recent-onset Narcolepsy type 1 reveals activation of the complement system
|
| Banda Nirmal |
RNA Profiling and protein expression studies in the synovium of both rheumatoid arthritis and post-traumatic injury identify causal pathogenic mechanisms for complement activation in both diseases
|
| Barr Johnny |
Immunopathology of Terminal Complement Activation and Complement C5 Blockade Creating a Pro-survival and Organ-protective Phenotype in Trauma
|
| Barrie Jennifer |
Complement inhibition prevents paranodal loop injury in an anti-GM1 antibody-mediated paranodal demyelinating mouse model.
|
| Barta Bálint |
The COVID-19 mRNA vaccine Comirnaty induces anaphylactic shock in an
anti-PEG hyperimmune pig model: Role of complement activation in cardiovascular, hematological and inflammatory mediator changes
|
| Barzaghi Federica |
The mannose-binding lectin (MBL) in MIS-C: relationship between MBL genotype, levels, and functional activity against SARS-CoV-2
|
| Bates Lucy |
Evaluation of minimal factor H therapy administered to kidneys during ex vivo normothermic perfusion as a treatment to improve ischaemia reperfusion injury
|
| Bathini Praveen |
A MaGical cASe:
a story on the cell-specific effects of C3-mediated neurodegeneration
|
| Batista Andre |
Generation and characterization of C3 inducible conditional KO Alzheimer’s-like mice
A MaGical cASe:
a story on the cell-specific effects of C3-mediated neurodegeneration
|
| Bechtler Clément |
Drug and Druggability: A new era in complement-targeted therapeutics and novel approaches off the conventional path
|
| Bevan Ryan |
The role of terminal pathway in driving pathology in dementia.
|
| Blagojevic Aleksandra |
Drug and Druggability: A new era in complement-targeted therapeutics and novel approaches off the conventional path
|
| Blom Anna |
Bacterial evasion strategy as basis for novel antimicrobial treatment.
|
| Boeke Jef |
Xenotransplantation: Using Genome Editing to Overcome Pig-to-Human Incompatibilities.
|
| Bondesan Simone |
The mannose-binding lectin (MBL) in MIS-C: relationship between MBL genotype, levels, and functional activity against SARS-CoV-2
|
| Borucki Davis |
The immune cell landscape of the injured brain and its relation to the complement system in traumatic brain injury
|
| Bottazzi Barbara |
The mannose-binding lectin (MBL) in MIS-C: relationship between MBL genotype, levels, and functional activity against SARS-CoV-2
Involvement of PTX3 and MBL in the clearance of SARS-CoV-2 infected lung airway epithelial cells
|
| Boudhabhay Idris |
In situ Complementomics in kidney diseases and cancer
Complement activation as a biomarker and pathogenic factor in rhabdomyolysis-induced acute kidney injury
|
| Bourdin Antonin |
In situ Complementomics in kidney diseases and cancer
|
| Bracke Laura |
Complement inhibition prevents paranodal loop injury in an anti-GM1 antibody-mediated paranodal demyelinating mouse model.
|
| Brekke Ole |
The Escherichia coli-induced platelet aggregation in human whole blood is inhibited by compstatin and is C3b dependent
|
| Busch Andreas |
Glycan structure optimization of moss produced human complement factor H markedly improves pharmacokinetic and pharmacodynamics properties in vivo.
|
| Butler Samuel |
A Novel Functional Properdin Assay – Studying the Positive AP Regulator and Complement Amplification Loop
|
| Caillard Sophie |
Ex vivo complement activation on endothelial cells: set up of a new functional tool to explore complement dysregulation
|
| Campbell Clare |
Complement inhibition prevents paranodal loop injury in an anti-GM1 antibody-mediated paranodal demyelinating mouse model.
|
| Cancio Leopoldo |
Immunopathology of Terminal Complement Activation and Complement C5 Blockade Creating a Pro-survival and Organ-protective Phenotype in Trauma
|
| Carrera Paola |
The mannose-binding lectin (MBL) in MIS-C: relationship between MBL genotype, levels, and functional activity against SARS-CoV-2
|
| Carroll Michael |
Generation and characterization of C3 inducible conditional KO Alzheimer’s-like mice
|
| Casari Giorgio |
The mannose-binding lectin (MBL) in MIS-C: relationship between MBL genotype, levels, and functional activity against SARS-CoV-2
|
| Cervenak László |
C1-INH complexes as markers for classical and lectin pathway activation
|
| Chauvet Sophie |
In situ Complementomics in kidney diseases and cancer
Impact of C3 and soluble C5b-9 levels on renal outcomes in C3 glomerulopathy : results from a national-wide retrospective cohort
Correlation of systemic and in situ biomarkers of complement activation with histopathological features and prognosis in C3 glomerulopathy.
|
| Chen Xi |
Compstatins abolish pathogenic fibroblast function associated with inflammatory tissue priming
|
| Christiansen Dorte |
The Escherichia coli-induced platelet aggregation in human whole blood is inhibited by compstatin and is C3b dependent
|
| Chu Shu-Hui |
New Shot on Goal: Targeting Inflammation and Synapse Loss to Suppress Alzheimer’s Disease
|
| Chung Hyewon |
Differential proteins including complement factor H in the aqueous humor from patients with dry age-related macular degeneration (AMD)
|
| Connelly Chloe |
Evaluation of minimal factor H therapy administered to kidneys during ex vivo normothermic perfusion as a treatment to improve ischaemia reperfusion injury
|
| Connolly E |
progressive neurological injury, early neurological deterioration and microvascular dysfunction following endovascular thrombectomy for larger vessel stroke: a target for anti-complement therapeutics
|
| Cooper Madison |
Evaluation of minimal factor H therapy administered to kidneys during ex vivo normothermic perfusion as a treatment to improve ischaemia reperfusion injury
|
| Cunningham Madelaine |
Complement inhibition prevents paranodal loop injury in an anti-GM1 antibody-mediated paranodal demyelinating mouse model.
|
| Curtin Karen |
Age-related Macular Degeneration: a Tale of Two RPE-centric Diseases, of Which Only One is Complement-driven
|
| Dabrowska-Schlepp Paulina |
Glycan structure optimization of moss produced human complement factor H markedly improves pharmacokinetic and pharmacodynamics properties in vivo.
|
| Delaere Jolien |
Complement inhibition prevents paranodal loop injury in an anti-GM1 antibody-mediated paranodal demyelinating mouse model.
|
| Delahaye Tim |
Complement inhibition prevents paranodal loop injury in an anti-GM1 antibody-mediated paranodal demyelinating mouse model.
|
| Desai Jigar |
C5a-licensed phagocytes drive sterilizing immunity during systemic fungal infection
|
| Domingo Enric |
Complement downregulation promotes an inflammatory signature that renders colorectal cancer susceptible to immunotherapy
|
| Donado Carlos |
Granzyme K activates a new complement pathway
|
| Duan Huiquan |
Continued investigations of modified DNA aptamers
as inhibitors of complement proteins and their complexes
|
| Dührkop Claudia |
An alternative binding and activation mechanism of native C3 induced by contact with biosurfaces without involvement of the thioester
|
| Duong Jean-Paul |
Correlation of systemic and in situ biomarkers of complement activation with histopathological features and prognosis in C3 glomerulopathy.
|
| Duval Anna |
Ex vivo complement activation on endothelial cells: set up of a new functional tool to explore complement dysregulation
Correlation of systemic and in situ biomarkers of complement activation with histopathological features and prognosis in C3 glomerulopathy.
|
| Ebert Roland |
An alternative binding and activation mechanism of native C3 induced by contact with biosurfaces without involvement of the thioester
|
| Edsall Peter |
Immunopathology of Terminal Complement Activation and Complement C5 Blockade Creating a Pro-survival and Organ-protective Phenotype in Trauma
|
| Ekdahl Kristina |
An alternative binding and activation mechanism of native C3 induced by contact with biosurfaces without involvement of the thioester
|
| Elvington Michelle |
Complement Factor B activation test specificity in the rapid test format: generation and characterization of new Ba neo-epitope specific monoclonal antibodies
|
| Emblem Åse |
The Escherichia coli-induced platelet aggregation in human whole blood is inhibited by compstatin and is C3b dependent
|
| Fageräng Beatrice |
Aspergillus fumigatus induces tumor necrosis factor release in a complement C3-dependent manner in lepirudin anticoagulated human whole blood
|
| Felsch Jannes |
Drug and Druggability: A new era in complement-targeted therapeutics and novel approaches off the conventional path
|
| Fleckenstein Monika |
Age-related Macular Degeneration: a Tale of Two RPE-centric Diseases, of Which Only One is Complement-driven
|
| Fosso Bruno |
Complement downregulation promotes an inflammatory signature that renders colorectal cancer susceptible to immunotherapy
|
| Frazer-Abel Ashley |
Stratification of patients with complement mediated diseases for complement targeted therapies: the perspective from the diagnostic complement laboratory
|
| fremeaux-Bacchi veronique |
Comprehensive genetic evaluation for the diagnosis of complement alternative pathway-mediated kidney diseases
Ex vivo complement activation on endothelial cells: set up of a new functional tool to explore complement dysregulation
Correlation of systemic and in situ biomarkers of complement activation with histopathological features and prognosis in C3 glomerulopathy.
|
| Frieri Camilla |
A new treatment paradigm for Paroxysmal Nocturnal Hemoglobinuria: the era of proximal complement inhibitors
|
| Friscic Jasna |
Compstatins abolish pathogenic fibroblast function associated with inflammatory tissue priming
|
| Fromell Karin |
An alternative binding and activation mechanism of native C3 induced by contact with biosurfaces without involvement of the thioester
|
| Fung Jenny |
Identification of genes involved in the protective response of C3aR in amyotrophic lateral sclerosis pathology
A detrimental role for complement C5aR1 activation in Huntington’s disease
|
| Gadeberg Trine |
structural insight on the function of properdin in the alternative pathway
|
| Garlanda Cecilia |
The mannose-binding lectin (MBL) in MIS-C: relationship between MBL genotype, levels, and functional activity against SARS-CoV-2
Involvement of PTX3 and MBL in the clearance of SARS-CoV-2 infected lung airway epithelial cells
|
| Garred Peter |
Aspergillus fumigatus induces tumor necrosis factor release in a complement C3-dependent manner in lepirudin anticoagulated human whole blood
|
| Geisbrecht Brian |
Continued investigations of modified DNA aptamers
as inhibitors of complement proteins and their complexes
|
| Gerogianni Alexandra |
The Escherichia coli-induced platelet aggregation in human whole blood is inhibited by compstatin and is C3b dependent
|
| Gibson Beth |
An Oral C5aR receptor antagonist blocks disease in the C3 gain-of-function mouse model of aHUS.
Evaluation of minimal factor H therapy administered to kidneys during ex vivo normothermic perfusion as a treatment to improve ischaemia reperfusion injury
|
| Golomingi Murielle |
Drug and Druggability: A new era in complement-targeted therapeutics and novel approaches off the conventional path
|
| Gomez-Arboledas Angela |
New Shot on Goal: Targeting Inflammation and Synapse Loss to Suppress Alzheimer’s Disease
|
| Götz Maximilian |
Aspergillus fumigatus induces tumor necrosis factor release in a complement C3-dependent manner in lepirudin anticoagulated human whole blood
|
| Griesemer Adam |
Xenotransplantation: Using Genome Editing to Overcome Pig-to-Human Incompatibilities.
|
| Grunenwald Anne |
Complement activation as a biomarker and pathogenic factor in rhabdomyolysis-induced acute kidney injury
|
| Guglietta Silvia |
The immune cell landscape of the injured brain and its relation to the complement system in traumatic brain injury
Complement downregulation promotes an inflammatory signature that renders colorectal cancer susceptible to immunotherapy
|
| Guido Poli |
Involvement of PTX3 and MBL in the clearance of SARS-CoV-2 infected lung airway epithelial cells
|
| Häffner Karsten |
Glycan structure optimization of moss produced human complement factor H markedly improves pharmacokinetic and pharmacodynamics properties in vivo.
|
| Hageman Gregory |
Age-related Macular Degeneration: a Tale of Two RPE-centric Diseases, of Which Only One is Complement-driven
|
| Hajishengallis George |
Mechanistic and therapeutic aspects in complement-driven periodontal disease
Probing C3 modulation in the intracellular space: Cellular internalization of compstatin-based C3 inhibitors and its functional implications
|
| Hamad Osama |
An alternative binding and activation mechanism of native C3 induced by contact with biosurfaces without involvement of the thioester
|
| Hasturk Hatice |
Mechanistic and therapeutic aspects in complement-driven periodontal disease
|
| Hevey Rachel |
Drug and Druggability: A new era in complement-targeted therapeutics and novel approaches off the conventional path
|
| Hill-Pryor Crystal |
Immunopathology of Terminal Complement Activation and Complement C5 Blockade Creating a Pro-survival and Organ-protective Phenotype in Trauma
|
| Hoffmann Markus |
Compstatins abolish pathogenic fibroblast function associated with inflammatory tissue priming
|
| Holers V Michael |
RNA Profiling and protein expression studies in the synovium of both rheumatoid arthritis and post-traumatic injury identify causal pathogenic mechanisms for complement activation in both diseases
|
| Hourcade Dennis |
Distinct cell-bound complement activation products associate with disease activity and immune transcriptional programs in systemic lupus erythematosus
|
| Hoyler Thomas |
An Oral C5aR receptor antagonist blocks disease in the C3 gain-of-function mouse model of aHUS.
|
| Hurler Lisa |
C1-INH complexes as markers for classical and lectin pathway activation
|
| Izzo Francesca |
The mannose-binding lectin (MBL) in MIS-C: relationship between MBL genotype, levels, and functional activity against SARS-CoV-2
|
| Jonsson Helena |
Granzyme K activates a new complement pathway
|
| Kajdácsi Erika |
C1-INH complexes as markers for classical and lectin pathway activation
|
| Karlsen Bård |
The Escherichia coli-induced platelet aggregation in human whole blood is inhibited by compstatin and is C3b dependent
|
| Kavian-Tessler Niloufar |
Involvement of PTX3 and MBL in the clearance of SARS-CoV-2 infected lung airway epithelial cells
|
| Keating Brendan |
Xenotransplantation: Using Genome Editing to Overcome Pig-to-Human Incompatibilities.
|
| Kemper Claudia |
C5a-licensed phagocytes drive sterilizing immunity during systemic fungal infection
|
| Khan Khyrul |
Generation and characterization of C3 inducible conditional KO Alzheimer’s-like mice
|
| Kim Alfred |
Distinct cell-bound complement activation products associate with disease activity and immune transcriptional programs in systemic lupus erythematosus
Xenotransplantation: Using Genome Editing to Overcome Pig-to-Human Incompatibilities.
|
| King Ben |
Cytosolic C3 in cellular homeostasis and defence
|
| Kirschfink Michael |
Stratification of patients with complement mediated diseases for complement targeted therapies: the perspective from the diagnostic complement laboratory
|
| Köhl Jörg |
C5a-licensed phagocytes drive sterilizing immunity during systemic fungal infection
|
| Konwar Swagata |
Glycan structure optimization of moss produced human complement factor H markedly improves pharmacokinetic and pharmacodynamics properties in vivo.
|
| Kozma Viktoria |
A Novel Functional Properdin Assay – Studying the Positive AP Regulator and Complement Amplification Loop
|
| Krieg Carsten |
Complement downregulation promotes an inflammatory signature that renders colorectal cancer susceptible to immunotherapy
The immune cell landscape of the injured brain and its relation to the complement system in traumatic brain injury
|
| Kulkarni Hrishikesh S |
Modulation of lung injury by tissue-specific C3 expression
|
| Lambris John |
Drug and Druggability: A new era in complement-targeted therapeutics and novel approaches off the conventional path
Mechanistic and therapeutic aspects in complement-driven periodontal disease
A new treatment paradigm for Paroxysmal Nocturnal Hemoglobinuria: the era of proximal complement inhibitors
Compstatins abolish pathogenic fibroblast function associated with inflammatory tissue priming
Probing C3 modulation in the intracellular space: Cellular internalization of compstatin-based C3 inhibitors and its functional implications
|
| Lambris & collaborators John |
The dawn of clinical C3 inhibition: the story, its milestones and what lies ahead
|
| Lamers Christina |
Drug and Druggability: A new era in complement-targeted therapeutics and novel approaches off the conventional path
|
| Landsem Anne |
The Escherichia coli-induced platelet aggregation in human whole blood is inhibited by compstatin and is C3b dependent
|
| Lau Corinna |
The Escherichia coli-induced platelet aggregation in human whole blood is inhibited by compstatin and is C3b dependent
|
| Le Tuan |
Immunopathology of Terminal Complement Activation and Complement C5 Blockade Creating a Pro-survival and Organ-protective Phenotype in Trauma
|
| Lee John |
Identification of genes involved in the protective response of C3aR in amyotrophic lateral sclerosis pathology
A detrimental role for complement C5aR1 activation in Huntington’s disease
Probing C3 modulation in the intracellular space: Cellular internalization of compstatin-based C3 inhibitors and its functional implications
|
| Lemere Cynthia |
Generation and characterization of C3 inducible conditional KO Alzheimer’s-like mice
A MaGical cASe:
a story on the cell-specific effects of C3-mediated neurodegeneration
|
| Lewis Sarah |
Aberrant protein S-nitrosylation of C3 activates phagocytosis of neuronal synapses by microglia in Alzheimer's disease
|
| Li Yansong |
Immunopathology of Terminal Complement Activation and Complement C5 Blockade Creating a Pro-survival and Organ-protective Phenotype in Trauma
Natural antibody targeted complement inhibitor ameliorates the development of chronic heart and lung transplant rejection
A MaGical cASe:
a story on the cell-specific effects of C3-mediated neurodegeneration
|
| Liang Heidi |
New Shot on Goal: Targeting Inflammation and Synapse Loss to Suppress Alzheimer’s Disease
|
| Lill Markus |
Drug and Druggability: A new era in complement-targeted therapeutics and novel approaches off the conventional path
|
| Lionakis Michail |
C5a-licensed phagocytes drive sterilizing immunity during systemic fungal infection
|
| Lipton Stuart A. |
Aberrant protein S-nitrosylation of C3 activates phagocytosis of neuronal synapses by microglia in Alzheimer's disease
|
| Liu Bin |
Immunopathology of Terminal Complement Activation and Complement C5 Blockade Creating a Pro-survival and Organ-protective Phenotype in Trauma
A detrimental role for complement C5aR1 activation in Huntington’s disease
Age-related Macular Degeneration: a Tale of Two RPE-centric Diseases, of Which Only One is Complement-driven
|
| Loupy Alexander |
Xenotransplantation: Using Genome Editing to Overcome Pig-to-Human Incompatibilities.
|
| Lund Brian |
Immunopathology of Terminal Complement Activation and Complement C5 Blockade Creating a Pro-survival and Organ-protective Phenotype in Trauma
|
| Mahendran Balaji |
Evaluation of minimal factor H therapy administered to kidneys during ex vivo normothermic perfusion as a treatment to improve ischaemia reperfusion injury
|
| Majdi Amine |
In situ Complementomics in kidney diseases and cancer
|
| Mangiola Massimo |
Xenotransplantation: Using Genome Editing to Overcome Pig-to-Human Incompatibilities.
|
| Månsson Cecilia |
A Novel Functional Properdin Assay – Studying the Positive AP Regulator and Complement Amplification Loop
|
| Mantovani Alberto |
The mannose-binding lectin (MBL) in MIS-C: relationship between MBL genotype, levels, and functional activity against SARS-CoV-2
|
| Marallag Jianina |
A detrimental role for complement C5aR1 activation in Huntington’s disease
|
| Marano Luana |
A new treatment paradigm for Paroxysmal Nocturnal Hemoglobinuria: the era of proximal complement inhibitors
|
| Marchbank Kevin |
An Oral C5aR receptor antagonist blocks disease in the C3 gain-of-function mouse model of aHUS.
Evaluation of minimal factor H therapy administered to kidneys during ex vivo normothermic perfusion as a treatment to improve ischaemia reperfusion injury
|
| Martinic Marianne |
An Oral C5aR receptor antagonist blocks disease in the C3 gain-of-function mouse model of aHUS.
|
| Marzano Marinella |
Complement downregulation promotes an inflammatory signature that renders colorectal cancer susceptible to immunotherapy
|
| Mastellos Dimitrios |
Mechanistic and therapeutic aspects in complement-driven periodontal disease
A new treatment paradigm for Paroxysmal Nocturnal Hemoglobinuria: the era of proximal complement inhibitors
Probing C3 modulation in the intracellular space: Cellular internalization of compstatin-based C3 inhibitors and its functional implications
|
| McGonigal Rhona |
Complement inhibition prevents paranodal loop injury in an anti-GM1 antibody-mediated paranodal demyelinating mouse model.
|
| Mehta Sapna |
Xenotransplantation: Using Genome Editing to Overcome Pig-to-Human Incompatibilities.
|
| Meuleman Marie Sophie |
In situ Complementomics in kidney diseases and cancer
Ex vivo complement activation on endothelial cells: set up of a new functional tool to explore complement dysregulation
Correlation of systemic and in situ biomarkers of complement activation with histopathological features and prognosis in C3 glomerulopathy.
|
| Mills Dan |
Complement Factor B activation test specificity in the rapid test format: generation and characterization of new Ba neo-epitope specific monoclonal antibodies
|
| Mitchell Lynne |
Distinct cell-bound complement activation products associate with disease activity and immune transcriptional programs in systemic lupus erythematosus
|
| Moazami Nader |
Xenotransplantation: Using Genome Editing to Overcome Pig-to-Human Incompatibilities.
|
| Mollnes Tom |
Aspergillus fumigatus induces tumor necrosis factor release in a complement C3-dependent manner in lepirudin anticoagulated human whole blood
The Escherichia coli-induced platelet aggregation in human whole blood is inhibited by compstatin and is C3b dependent
A review of the double inhibition of complement and TLRs - from the origin on the bench through animal studies and possible clinical applications.
|
| Montgomery Robert |
Xenotransplantation: Using Genome Editing to Overcome Pig-to-Human Incompatibilities.
|
| Morgan Paul |
The role of terminal pathway in driving pathology in dementia.
Complement in neuroinflammatory and neurodegenerative diseases.
|
| Mortazavi Ali |
New Shot on Goal: Targeting Inflammation and Synapse Loss to Suppress Alzheimer’s Disease
|
| Murphy Mark |
An Oral C5aR receptor antagonist blocks disease in the C3 gain-of-function mouse model of aHUS.
|
| Nakamura Tomohiro |
Aberrant protein S-nitrosylation of C3 activates phagocytosis of neuronal synapses by microglia in Alzheimer's disease
|
| Nilsson Camilla |
A Novel Functional Properdin Assay – Studying the Positive AP Regulator and Complement Amplification Loop
The Escherichia coli-induced platelet aggregation in human whole blood is inhibited by compstatin and is C3b dependent
An alternative binding and activation mechanism of native C3 induced by contact with biosurfaces without involvement of the thioester
Aspergillus fumigatus induces tumor necrosis factor release in a complement C3-dependent manner in lepirudin anticoagulated human whole blood
|
| Nunn Miles |
Immunopathology of Terminal Complement Activation and Complement C5 Blockade Creating a Pro-survival and Organ-protective Phenotype in Trauma
|
| O'Luanaigh Niamh |
Complement Factor B activation test specificity in the rapid test format: generation and characterization of new Ba neo-epitope specific monoclonal antibodies
|
| O'Neill Mollie |
Complement Factor B activation test specificity in the rapid test format: generation and characterization of new Ba neo-epitope specific monoclonal antibodies
|
| Oh Chang-ki |
Aberrant protein S-nitrosylation of C3 activates phagocytosis of neuronal synapses by microglia in Alzheimer's disease
|
| Olcina Monica |
Understanding the role of C5aR1 in tumours with immunosuppressive microenvironments
Complement downregulation promotes an inflammatory signature that renders colorectal cancer susceptible to immunotherapy
|
| Pagani Isabel |
The mannose-binding lectin (MBL) in MIS-C: relationship between MBL genotype, levels, and functional activity against SARS-CoV-2
Involvement of PTX3 and MBL in the clearance of SARS-CoV-2 infected lung airway epithelial cells
|
| Panse Jens |
Glycan structure optimization of moss produced human complement factor H markedly improves pharmacokinetic and pharmacodynamics properties in vivo.
|
| Papavergi Maria-Tzousi |
A MaGical cASe:
a story on the cell-specific effects of C3-mediated neurodegeneration
|
| Pappas Chris |
Age-related Macular Degeneration: a Tale of Two RPE-centric Diseases, of Which Only One is Complement-driven
|
| Pappworth Isabel |
An Oral C5aR receptor antagonist blocks disease in the C3 gain-of-function mouse model of aHUS.
|
| Patel Kunal |
Natural antibody targeted complement inhibitor ameliorates the development of chronic heart and lung transplant rejection
|
| Pekna Marcela |
The therapeutic potential of C3aR agonists in the post-acute phase after stroke
|
| Pio Ruben |
The C5a/C5aR1 axis in tumor-associated myeloid cells
|
| Pouw Richard |
Drug and Druggability: A new era in complement-targeted therapeutics and novel approaches off the conventional path
|
| Prohászka Zoltán |
Stratification of patients with complement mediated diseases for complement targeted therapies: the perspective from the diagnostic complement laboratory
C1-INH complexes as markers for classical and lectin pathway activation
|
| Pusateri Anthony |
Immunopathology of Terminal Complement Activation and Complement C5 Blockade Creating a Pro-survival and Organ-protective Phenotype in Trauma
|
| Qamar Ali |
A Novel Functional Properdin Assay – Studying the Positive AP Regulator and Complement Amplification Loop
|
| Rabbani Said |
Drug and Druggability: A new era in complement-targeted therapeutics and novel approaches off the conventional path
|
| Radovits Tamas |
The COVID-19 mRNA vaccine Comirnaty induces anaphylactic shock in an
anti-PEG hyperimmune pig model: Role of complement activation in cardiovascular, hematological and inflammatory mediator changes
|
| RATAJCZAK MARIUSZ |
Both liver-derived and intracellular complement modulate hematopoietic stem/progenitor cell metabolism and stress response.
|
| Revel Margot |
In situ Complementomics in kidney diseases and cancer
|
| Richards Burt |
Age-related Macular Degeneration: a Tale of Two RPE-centric Diseases, of Which Only One is Complement-driven
|
| Ricklin Daniel |
Drug and Druggability: A new era in complement-targeted therapeutics and novel approaches off the conventional path
|
| Risitano Antonio M. |
A new treatment paradigm for Paroxysmal Nocturnal Hemoglobinuria: the era of proximal complement inhibitors
|
| Roberson Elisha |
Distinct cell-bound complement activation products associate with disease activity and immune transcriptional programs in systemic lupus erythematosus
|
| Robinson Mark |
Complement downregulation promotes an inflammatory signature that renders colorectal cancer susceptible to immunotherapy
|
| Roumenina Lubka |
In situ Complementomics in kidney diseases and cancer
Ex vivo complement activation on endothelial cells: set up of a new functional tool to explore complement dysregulation
Complement activation as a biomarker and pathogenic factor in rhabdomyolysis-induced acute kidney injury
Intracellular Functions of Complement proteins in health and in Diseases affecting
the Kidney
|
| Rumano Merita |
Probing C3 modulation in the intracellular space: Cellular internalization of compstatin-based C3 inhibitors and its functional implications
|
| Rüthemann Peter |
Drug and Druggability: A new era in complement-targeted therapeutics and novel approaches off the conventional path
|
| Saido Takaomi |
Generation and characterization of C3 inducible conditional KO Alzheimer’s-like mice
|
| Saito Takashi |
Generation and characterization of C3 inducible conditional KO Alzheimer’s-like mice
|
| Sasaguri Hiroki |
Generation and characterization of C3 inducible conditional KO Alzheimer’s-like mice
|
| Schahrer Emily |
Aberrant protein S-nitrosylation of C3 activates phagocytosis of neuronal synapses by microglia in Alzheimer's disease
|
| Schartz Nicole |
New Shot on Goal: Targeting Inflammation and Synapse Loss to Suppress Alzheimer’s Disease
|
| Schmidt Christoph |
Drug and Druggability: A new era in complement-targeted therapeutics and novel approaches off the conventional path
Complement Factor B activation test specificity in the rapid test format: generation and characterization of new Ba neo-epitope specific monoclonal antibodies
|
| Schmitz-Valckenberg Steffen |
Age-related Macular Degeneration: a Tale of Two RPE-centric Diseases, of Which Only One is Complement-driven
|
| Schroeder Verena |
Drug and Druggability: A new era in complement-targeted therapeutics and novel approaches off the conventional path
Generation and characterization of C3 inducible conditional KO Alzheimer’s-like mice
|
| Schwardt Oliver |
Drug and Druggability: A new era in complement-targeted therapeutics and novel approaches off the conventional path
|
| Schwenkert Michael |
A Novel Functional Properdin Assay – Studying the Positive AP Regulator and Complement Amplification Loop
|
| Seager Nathan |
Age-related Macular Degeneration: a Tale of Two RPE-centric Diseases, of Which Only One is Complement-driven
|
| Segerstein Therese |
A Novel Functional Properdin Assay – Studying the Positive AP Regulator and Complement Amplification Loop
|
| Sheerin Neil |
Evaluation of minimal factor H therapy administered to kidneys during ex vivo normothermic perfusion as a treatment to improve ischaemia reperfusion injury
|
| Shoibonov Batozhab |
Determining the activity of the alternative and lectin path of the complement system in the fibrinogen coagulation test to predict of the severity of the COVID-19
|
| Sievert Christian |
Glycan structure optimization of moss produced human complement factor H markedly improves pharmacokinetic and pharmacodynamics properties in vivo.
|
| Simovic Milomir |
Immunopathology of Terminal Complement Activation and Complement C5 Blockade Creating a Pro-survival and Organ-protective Phenotype in Trauma
|
| Singh Brijendra |
Generation and characterization of C3 inducible conditional KO Alzheimer’s-like mice
A MaGical cASe:
a story on the cell-specific effects of C3-mediated neurodegeneration
|
| Sinkovits György |
C1-INH complexes as markers for classical and lectin pathway activation
|
| Sironi Marina |
The mannose-binding lectin (MBL) in MIS-C: relationship between MBL genotype, levels, and functional activity against SARS-CoV-2
|
| Skjoedt Mikkel-Ole |
The complement regulator MAP-1 interacts with activated FXII and attenuates the coagulation system
|
| Smiesko Martin |
Drug and Druggability: A new era in complement-targeted therapeutics and novel approaches off the conventional path
|
| Smith Deane |
Xenotransplantation: Using Genome Editing to Overcome Pig-to-Human Incompatibilities.
|
| Smith-Jackson Kate |
An Oral C5aR receptor antagonist blocks disease in the C3 gain-of-function mouse model of aHUS.
|
| Spooner Emma |
Generation and characterization of C3 inducible conditional KO Alzheimer’s-like mice
A MaGical cASe:
a story on the cell-specific effects of C3-mediated neurodegeneration
|
| Stern Jeffrey |
Xenotransplantation: Using Genome Editing to Overcome Pig-to-Human Incompatibilities.
|
| Stravalaci Matteo |
The mannose-binding lectin (MBL) in MIS-C: relationship between MBL genotype, levels, and functional activity against SARS-CoV-2
Involvement of PTX3 and MBL in the clearance of SARS-CoV-2 infected lung airway epithelial cells
|
| Szebeni Janos |
The COVID-19 mRNA vaccine Comirnaty induces anaphylactic shock in an
anti-PEG hyperimmune pig model: Role of complement activation in cardiovascular, hematological and inflammatory mediator changes
|
| Tannenbaum Steven R. |
Aberrant protein S-nitrosylation of C3 activates phagocytosis of neuronal synapses by microglia in Alzheimer's disease
|
| Taylor Ronald |
FcγR-mediated Trogocytosis 2.0: Revisiting History gives rise to a Unifying Hypothesis
|
| Tenner Andrea |
New Shot on Goal: Targeting Inflammation and Synapse Loss to Suppress Alzheimer’s Disease
|
| Teramura Yuji |
An alternative binding and activation mechanism of native C3 induced by contact with biosurfaces without involvement of the thioester
|
| Theisen Erin |
Granzyme K activates a new complement pathway
|
| Thomas Julie |
Age-related Macular Degeneration: a Tale of Two RPE-centric Diseases, of Which Only One is Complement-driven
|
| Thompson Emily |
Evaluation of minimal factor H therapy administered to kidneys during ex vivo normothermic perfusion as a treatment to improve ischaemia reperfusion injury
|
| Tingle Samuel |
Evaluation of minimal factor H therapy administered to kidneys during ex vivo normothermic perfusion as a treatment to improve ischaemia reperfusion injury
|
| Tomlinson Stephen |
Natural antibody targeted complement inhibitor ameliorates the development of chronic heart and lung transplant rejection
The immune cell landscape of the injured brain and its relation to the complement system in traumatic brain injury
|
| Toonen Erik |
C1-INH complexes as markers for classical and lectin pathway activation
|
| Toutonji Amer |
The immune cell landscape of the injured brain and its relation to the complement system in traumatic brain injury
|
| Trudler Dorit |
Aberrant protein S-nitrosylation of C3 activates phagocytosis of neuronal synapses by microglia in Alzheimer's disease
|
| Tschongov Todor |
Glycan structure optimization of moss produced human complement factor H markedly improves pharmacokinetic and pharmacodynamics properties in vivo.
|
| Tu Zhenxiao |
Natural antibody targeted complement inhibitor ameliorates the development of chronic heart and lung transplant rejection
|
| Umnyakova Ekaterina |
Drug and Druggability: A new era in complement-targeted therapeutics and novel approaches off the conventional path
|
| van Bree Bregje |
C1-INH complexes as markers for classical and lectin pathway activation
|
| Van de Walle Inge |
Complement inhibition prevents paranodal loop injury in an anti-GM1 antibody-mediated paranodal demyelinating mouse model.
|
| Vicenzi Elisa |
The mannose-binding lectin (MBL) in MIS-C: relationship between MBL genotype, levels, and functional activity against SARS-CoV-2
Involvement of PTX3 and MBL in the clearance of SARS-CoV-2 infected lung airway epithelial cells
|
| Vogt Stephanie |
Drug and Druggability: A new era in complement-targeted therapeutics and novel approaches off the conventional path
|
| Weber Lukas |
Complement downregulation promotes an inflammatory signature that renders colorectal cancer susceptible to immunotherapy
|
| Widmer Kevin |
Drug and Druggability: A new era in complement-targeted therapeutics and novel approaches off the conventional path
|
| Williams Brandi |
Age-related Macular Degeneration: a Tale of Two RPE-centric Diseases, of Which Only One is Complement-driven
|
| Willison Hugh |
Complement inhibition prevents paranodal loop injury in an anti-GM1 antibody-mediated paranodal demyelinating mouse model.
|
| Wilson Colin |
Evaluation of minimal factor H therapy administered to kidneys during ex vivo normothermic perfusion as a treatment to improve ischaemia reperfusion injury
|
| Wishnok John S. |
Aberrant protein S-nitrosylation of C3 activates phagocytosis of neuronal synapses by microglia in Alzheimer's disease
|
| Woodruff Trent |
Identification of genes involved in the protective response of C3aR in amyotrophic lateral sclerosis pathology
A detrimental role for complement C5aR1 activation in Huntington’s disease
|
| Würzner Reinhard |
C1-INH complexes as markers for classical and lectin pathway activation
|
| Yancopoulou Despina |
Mechanistic and therapeutic aspects in complement-driven periodontal disease
A new treatment paradigm for Paroxysmal Nocturnal Hemoglobinuria: the era of proximal complement inhibitors
Probing C3 modulation in the intracellular space: Cellular internalization of compstatin-based C3 inhibitors and its functional implications
|
| Yang Zhansheng |
Immunopathology of Terminal Complement Activation and Complement C5 Blockade Creating a Pro-survival and Organ-protective Phenotype in Trauma
Aberrant protein S-nitrosylation of C3 activates phagocytosis of neuronal synapses by microglia in Alzheimer's disease
|
| Yao Denggao |
Complement inhibition prevents paranodal loop injury in an anti-GM1 antibody-mediated paranodal demyelinating mouse model.
|
| Zelek Wioleta |
The role of terminal pathway in driving pathology in dementia.
|
| Zhang Ying |
Continued investigations of modified DNA aptamers
as inhibitors of complement proteins and their complexes
|
| Zhong Hang |
The mannose-binding lectin (MBL) in MIS-C: relationship between MBL genotype, levels, and functional activity against SARS-CoV-2
Involvement of PTX3 and MBL in the clearance of SARS-CoV-2 infected lung airway epithelial cells
|
| Zoia Elena |
The mannose-binding lectin (MBL) in MIS-C: relationship between MBL genotype, levels, and functional activity against SARS-CoV-2
|
| Zouache Moussa |
Age-related Macular Degeneration: a Tale of Two RPE-centric Diseases, of Which Only One is Complement-driven
|
